Union Health Ministry Proposes Tighter Curbs on Advertising of Prescription Drugs by Retailers and Wholesalers

1. At a Glance

• What it is: A draft amendment to the Drugs Rules, 1945. It adds sub-rule (22) to Rule 65 so that drug retailers, wholesalers and distributors also need previous sanction of the Central Government before advertising Schedule H, H1 and X drugs [1].
• Gap it closes: Manufacturers already needed prior sanction to advertise these drugs. The rules did not clearly cover entities that sell and distribute them [1].
• Public-health aim: Stop unauthorised promotion of prescription-only medicines and reduce inappropriate self-medication, especially with antibiotics and psychotropic drugs [1].
• UPSC value: Links drug regulation, antimicrobial resistance (AMR), consumer protection and the delegated-legislation process (draft rules → objections → final notification).

2. Why in the News

• 28 Sep 2026: The draft amendment was notified through Gazette Notification G.S.R. 861(E) [1].
• 9 Oct 2026: The Ministry of Health and Family Welfare (MoHFW) announced the proposal through PIB [1].
• The public has 30 days to file objections and suggestions. The 30 days start from the date copies of the Gazette are made available to the public [1].

3. Background & Evolution

• 1940: The Drugs and Cosmetics Act was enacted as Act No. 23 of 1940, dated 10 April 1940 [6].
• 1945: The Drugs and Cosmetics Rules, 1945 were framed under the Act. The current PIB release calls them the "Drugs Rules, 1945" [4][1].
• 1954: The Drugs and Magic Remedies (Objectionable Advertisements) Act was passed "to control the advertisement of drugs in certain cases" and to ban advertising of remedies claimed to have magic qualities [7].
• 30 Aug 2013: Schedule H1 was created by GSR 588(E). It covers certain 3rd- and 4th-generation antibiotics, some habit-forming drugs and anti-TB drugs [3].
• 2015: The Rules were amended so that no advertisement of Schedule H, H1 or X drugs can be made without previous sanction of the Central Government. In practice this applied to manufacturers [2][1].
• 16 Feb 2026: The 93rd meeting of the DTAB recommended rules on advertising by drug sale and distribution licence holders [1].
• 28 Sep 2026: The draft G.S.R. 861(E) was notified, extending the advertising curb to licensed sellers and distributors [1].

4. Core Static Facts

Item	Fact
Ministry	Ministry of Health and Family Welfare [1]
Parent Act	Drugs and Cosmetics Act, 1940 (Act 23 of 1940) [6]
Rules amended	Drugs Rules, 1945, Rule 65 (conditions of licences for sale of drugs) [1][4]
New provision	Sub-rule (22) of Rule 65 [1]
Who is covered	Holders of licences to sell, stock, exhibit or offer for sale, or distribute drugs, including retail and wholesale licence holders [1]
Drugs covered	Schedule H, Schedule H1, Schedule X [1]
Requirement	No advertisement except with the previous sanction of the Central Government [1]
Notification	G.S.R. 861(E), 28 Sep 2026 (draft) [1]
Advisory body	Drugs Technical Advisory Board (DTAB), set up under Section 5 of the 1940 Act to advise the Central and State Governments on technical matters [5]
Recommending meeting	93rd DTAB meeting, 16 Feb 2026 [1]
Comment window	30 days from public availability of the Gazette [1]

Key terms

• Schedule H / Schedule X: These drugs may be sold by retail only on the prescription of a Registered Medical Practitioner [3].
• Schedule H1 sale conditions:
• Each sale must be entered in a separate register: prescriber's name and address, patient's name, drug name and quantity.

• Records must be kept for 3 years and be open for inspection [4].

• Schedule H1 labelling:

• A red "Rx" symbol on the top-left corner of the label.
• A warning inside a box with a red border: dangerous to take except on medical advice; not to be sold by retail without an RMP's prescription [4].

5. Multi-Dimensional Analysis

Legal / Constitutional

• The change is delegated legislation: rules made under the 1940 Act, with a draft-and-objections step before final notification [1].
• It extends the 2015 prior-sanction rule from manufacturers to the whole supply chain. Previously, sellers and distributors were not explicitly covered [2][1].
• It sits alongside the DMR Act, 1954, which bans objectionable drug advertisements. The new rule is a separate, licence-linked control through the Drugs Rules [7][1].

Public Health / Social

• It targets self-medication with drugs that need medical supervision: antibiotics, psychotropics and other prescription-only medicines [1].
• Schedule H1 already covers antibiotics and anti-TB drugs [3]. Stopping retail promotion supports AMR containment and protects TB treatment from misuse.
• Vulnerable groups are most at risk from pharmacy-led promotion of prescription drugs: low-literacy consumers and people without easy access to a doctor.

Economic

• Retail and wholesale chemists lose a promotional channel, including discount and "deal" style advertising of prescription drugs.
• Compliance costs rise because each such advertisement needs a Central sanction. Large chains and online platforms will feel this most.

Ethical / Governance

• Supply-chain-wide accountability: advertising duties now attach to every licence holder, not only the manufacturer [1].
• Participatory rule-making: stakeholders and the public can file objections within 30 days [1].
• Expert-driven policy: the change follows the 93rd DTAB meeting, the statutory technical body [1][5].

Administrative

• Centre–State split: the Central Government grants advertising sanction [1], while retail and wholesale licences are mostly issued and policed by State drug controllers. Coordination will be needed.
• Enforcement challenge: spotting unauthorised advertisements across thousands of chemists and digital channels.
• Definitional gap: what counts as an "advertisement" in digital, app-based or in-store formats will matter when the rule is applied.

6. Recent Developments (last 12–18 months)

• 16 Feb 2026: The 93rd DTAB meeting considered and recommended advertising rules for sale and distribution licence holders [1].
• 28 Sep 2026: The draft G.S.R. 861(E) was published in the Gazette [1].
• 9 Oct 2026: The PIB press release (Release ID 2321172) invited public objections and suggestions within 30 days [1].
• Next step: The Central Government will consider the submissions and then publish the final amendment [1].

7. Prelims Hooks

• The draft amendment inserts sub-rule (22) under Rule 65 of the Drugs Rules, 1945 [1].
• It was notified via G.S.R. 861(E) dated 28 September 2026 [1].
• It follows the 93rd DTAB meeting held on 16 February 2026 [1].
• Schedules covered: H, H1 and X. Schedule G and OTC drugs are not mentioned [1].
• The authority that grants sanction is the Central Government, not State Licensing Authorities [1].
• The 2015 amendment first required prior Central sanction for advertising Schedule H, H1 and X drugs [2].
• Schedule H1 was introduced by GSR 588(E), 30 Aug 2013 [3].
• Schedule H1 covers 3rd/4th-generation antibiotics, certain habit-forming drugs and anti-TB drugs [3].
• Schedule H1 sale records are kept in a separate register for 3 years [4].
• Schedule H1 label: red "Rx" at top-left plus a warning in a red-bordered box [4].
• DTAB is constituted under Section 5 of the Drugs and Cosmetics Act, 1940 [5].
• The Drugs and Cosmetics Act is Act No. 23 of 1940 (10 April 1940) [6].
• The Drugs and Magic Remedies (Objectionable Advertisements) Act dates from 1954 [7].
• Objections may be filed within 30 days of public availability of the Gazette, not 30 days from the PIB release [1].

8. Why Banning Ads Will Not Stop Sales Without a Prescription

• The real problem is the sale, not the advertisement
• Schedule H and X drugs can already be sold only on a doctor's prescription [3]. Advertising them was never what made that legal or illegal.
• When a chemist sells antibiotics without a prescription, no advertisement is involved. The customer asks and the chemist sells.

• So the new sub-rule (22) removes one push towards self-medication (taking medicine without a doctor's advice). The bigger cause, selling at the counter without a prescription, stays the same [1].

• The chemist both promotes the drug and decides who gets it

• The law relies on the chemist to refuse a sale when there is no prescription [3].
• That same chemist earns money from every sale. An advertising rule does not change this conflict of interest.

• So the advertising rule only works if inspectors also check whether chemists actually ask for prescriptions.

• The paper trail exists only for Schedule H1

• For H1 drugs, each sale must go into a separate register with the prescriber's and patient's names, kept for 3 years [4].
• Ordinary Schedule H drugs have no such register. An inspector checking them has no written record to follow.
• So the new rule will be easiest to back up for H1 antibiotics and hardest for the much bigger Schedule H list.

9. The Centre Gives Permission, but the States Must Punish

• The rule is placed among licence conditions, so punishment means action on the licence
• Sub-rule (22) goes into Rule 65, which lists the conditions attached to a licence to sell drugs [1][4].
• If a seller breaks a licence condition, the usual penalty is suspension or cancellation of the licence under Rule 66 [4].

• The State Licensing Authority takes that action, not the Centre [4].

• This splits one decision between two governments

• The Central Government decides whether an advertisement is allowed [1].
• The State drug controller has to find the illegal advertisement and then act on the licence.

• A State inspector who finds an advertisement cannot tell if it is legal without knowing whether the Centre sanctioned it. Nothing in the draft says the Centre must publish a list of sanctions [1].

• Why this matters for the exam

• It is a clear example of a Centre–State gap in a concurrent subject: one level makes the rule and gives permission, the other has the inspectors.

10. Who the Rule Cannot Reach: Apps and Influencers Without a Licence

• The rule applies only to people who hold a drug licence
• It covers holders of licences to sell, stock, exhibit, offer for sale or distribute drugs [1].
• A health app, a social-media influencer or an aggregator website that does not hold a sale licence is not a licence holder. It has no licence that can be suspended under this rule.

• Much of today's medicine promotion happens through exactly these channels.

• The older advertising law has narrow coverage

• The DMR Act, 1954 (Drugs and Magic Remedies Act) bans ads only for certain listed diseases and for "magic" cure claims [7].
• An ordinary app ad saying "order antibiotics, 20% off" may not fit neatly under either law.
• So the gap in the rules moves from wholesalers and retailers to unlicensed digital middlemen.

11. The Chemists' Strongest Objection: Price Information Is Not Promotion

• The objection
• Schedule H is a long list. It includes many medicines that patients with long-term illnesses buy every month, not only antibiotics [3].
• Chemists will argue that a board saying "15% off on all medicines" helps poor patients find cheaper medicine. It does not push anyone to take a drug they do not need.

• If such a notice needs Central sanction, price competition between chemists could fall, and patients would pay more.

• What is right about it

• A patient with a prescription is not self-medicating. Telling that patient where the drug is cheaper does not cause misuse.

• The draft does not separate price or availability information from promotion of a specific drug [1].

• Why the rule is still justified

• The harm the Ministry is targeting is promotion that creates demand: "antibiotics for cold, buy now" [1].
• For H1 antibiotics and Schedule X drugs, even a discount ad can encourage people to buy without a doctor, and that feeds AMR (antimicrobial resistance: germs no longer killed by medicines) [3].
• So the fair answer is to narrow the rule, not drop it: allow plain price lists, but control ads that name or push a particular prescription drug.

12. What the Final Rule Should Fix

• MoHFW should define "advertisement" in the rule itself, using the DMR Act wording
• The DMR Act, 1954 already defines advertisement widely: any notice, circular, label, wrapper, document, or announcement made orally or by light, sound or smoke [7].

• Copying this wording, and adding apps, websites and social media, would close the digital gap.

• MoHFW should allow plain price and stock information

• A general notice of discounts, with no drug named, should not need Central sanction.

• This answers the chemists' fair concern without weakening control over antibiotic and Schedule X promotion.

• The Centre should publish every sanction it grants

• A public list would let State drug controllers check quickly whether an ad they find is legal.

• Without it, the Centre–State split described above makes enforcement slow.

• DTAB should next look at unlicensed online promoters

• DTAB is the statutory technical adviser under Section 5 of the 1940 Act [5]. It already recommended this rule at its 93rd meeting [1].

• Its next step should be a rule that reaches platforms and promoters that hold no sale licence.

• State drug controllers should check prescriptions along with ads

• The H1 register (prescriber, patient, drug, quantity, kept 3 years) gives inspectors a ready record to audit [4].
• Checking that register along with ad compliance targets the counter sale, which is the real driver of self-medication.

13. Anchors for Answers

• Report/Committee: 93rd meeting of the Drugs Technical Advisory Board (DTAB), 16 Feb 2026, recommended advertising curbs on sale and distribution licence holders [1]
• Law/Case: Rule 65(22) (draft) and Rule 66 (licence suspension or cancellation), Drugs Rules, 1945 [1][4]; definition of "advertisement" in Section 2(a) of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 [7]
• Scheme: Schedule H1 register system: a sale-level record (prescriber, patient, drug, quantity, kept 3 years) that inspectors can audit for antibiotic misuse [4]

14. Mains Relevance

• GS-II: Issues relating to the development and management of the social sector and services relating to Health; government policies and interventions; statutory and regulatory bodies.
• GS-III: Science and technology in everyday life (AMR, as a related angle).
• GS-IV: Ethics in business and pharmaceutical marketing; corporate responsibility.
• Possible question stems: 1. Unregulated promotion of prescription drugs fuels self-medication and antimicrobial resistance in India. Critically examine the adequacy of India's legal framework on drug advertising in light of recent amendments to the Drugs Rules, 1945. (15 marks) 2. Extending regulatory accountability across the pharmaceutical supply chain is essential for patient safety. Discuss with reference to Schedule H, H1 and X drugs. (10 marks) 3. Discuss the role of the Drugs Technical Advisory Board in India's drug regulation and the challenges of Centre–State coordination in enforcing drug laws. (10 marks)

15. Related Topics to Study Next

• Drugs and Cosmetics Act, 1940 and the proposed Drugs, Medical Devices and Cosmetics Bill: the parent law and the reform debate around it.
• Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954: the other main law on drug advertising [7].
• Supreme Court on misleading health advertisements (2024): see the SC judgment of 13 Aug 2024 (2024 INSC 605) on the sci.gov.in record. Not verified for this note; read it directly.
• AMR and the National Action Plan on AMR / Red Line campaign: Schedule H1 is the regulatory tool against antibiotic misuse [3].
• CDSCO / DCGI and State drug controllers: who regulates what, and the federal division of drug regulation.
• E-pharmacy regulation: online sale and promotion of prescription drugs is the next enforcement frontier.
• NDPS Act, 1985: psychotropics overlap with Schedule X, and its interface with drug rules.
• Consumer Protection Act, 2019 and CCPA guidelines on misleading advertisements: a parallel consumer-law route.

16. NCERT Concepts to Revise

• Delegated legislation (Polity): The change is a draft rule under the 1940 Act, with a 30-day objections step before final notification.
• Consumer protection (Economy): The curb protects patients from misleading promotion of prescription drugs and from unsafe self-medication.
• Supply chain (Economy): The rule extends advertising accountability from manufacturers to wholesalers, distributors and retailers across the whole drug supply chain.
• Aggregator (Economy): Apps and aggregator sites without a sale licence fall outside the rule, leaving a gap in digital promotion.
• Governance (Polity): The note covers how rules are made, enforced and shared between Centre and States, such as drug controllers.

17. Common Errors / Trap Areas

• Restriction already applied to manufacturers (since 2015): the 2026 draft extends it to sellers and distributors. It is not a brand-new ban [2][1].
• Sanctioning authority: it is the Central Government, not State drug controllers or the DTAB. The DTAB only advises [1][5].
• Mixing up schedules:
• H1 = 2013, register for 3 years, antibiotics, anti-TB and habit-forming drugs [3][4].

• X = also prescription-only [3]; aspirants often confuse it with NDPS schedules.

• Status: G.S.R. 861(E) is a draft, not a final rule. The Gazette date (28 Sep) is earlier than the PIB date (9 Oct) [1].

• Wrong Act: the amendment is to the Drugs Rules, 1945, framed under the 1940 Act. It does not amend the DMR Act, 1954 [1][7].